{"page":{"totalFilteredElements":347},"studies":[{"active":true,"description":"

Prospektive Beobachtungsstudie molekulares Tumorboard am CCC Mainfranken des Universitätsklinikums Würzburg

","eudractNumber":null,"id":7637,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn1","name":"Gebärmutterkrebs (Uteruskarzinom)"},{"id":"gyn2","name":"Gebärmutterhalskrebs (Zervixkarzinom)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"pro","name":"Prostatakrebs"},{"id":"uro","name":"Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)"},{"id":"uro1","name":"Nierenzellkarzinom"},{"id":"uro2","name":"Tumoren der ableitenden Harnwege (Nierenbecken, Ureter, Harnblase, Harnröhre)"},{"id":"uro3","name":"Hodenkarzinom"},{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio1","name":"Karzinom der Speiseröhre (Oesophaguskarzinom, inkl. gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"gio4","name":"Weitere Tumoren des Verdauungstraktes (z.B. Gastrointestinale Stromatumoren, GIST)"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"giu4","name":"Weitere Tumoren des Verdauungstraktes (z.B. Gastrointestinale Stromatumoren, GIST)"},{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno1","name":"Mundhöhlenkarzinom, Rachenkarzinom, inkl. Mundboden- und Zungengrundkarzinom"},{"id":"hno2","name":"Kehlkopfkrebs (Larynxkarzinom)"},{"id":"hno3","name":"Kopf-Hals-Malignome"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"},{"id":"zns","name":"Hirntumore (ZNS Tumore)"},{"id":"zns1","name":"Astrozytäre Gliome (Astrozytom, Glioblastom)"},{"id":"zns2","name":"Meningeom"},{"id":"zns3","name":"Akustikusneurinom (Vestibularis-Schwannom)"},{"id":"zns4","name":"Weitere Hirntumoren"},{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"},{"id":"hau2","name":"Basaliom"},{"id":"hau4","name":"Merkelzellkarzinom"},{"id":"sar","name":"Sarkome"},{"id":"sar1","name":"Knochensarkome (Ewing-Sarkom, Osteosarkom etc.)"},{"id":"sar2","name":"Weichteilsarkome (Liposarkom, Leiomyosarkom, etc.)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[{"name":"Sequenzierungspanel","id":"mt_58"}],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2022-04-19T14:01:24+02:00","shortTitle":"Prospektive Beobachtungsstudie molekulares Tumorboard am CCC Mainfranken des Universitätsklinikums Würzburg","therapeutical":true,"therapyLines":[]},{"active":true,"description":"

NAFLD Kohorte Dr. Rau - Prospektive Verlaufsbeobachtung bei Patienten mit Nicht-alkoholischer Fettlebererkrankung\n(Fettleberkohorte)

","eudractNumber":null,"id":2264,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2012-10-01T09:56:17+02:00","shortTitle":"Prospektive Verlaufsbeobachtung bei Patienten mit Nicht-alkoholischer Fettlebererkrankung (Fettleberkohorte)","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Prospektive NIS of trastuzumab Deruxtecan (T-DXd) for adult patients with advanced HER2-positive gastric or Gastroesophageal junction adenocarcinoma who have received a prior Tratsuzumab based regimen , accompanied by a disease registry of patients treated with conventional therapies in a real world setting","eudractNumber":null,"id":10657,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-04-24T09:00:30+02:00","shortTitle":"Prosperity","therapeutical":false,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"The Prophet-Trial: A Multicenter \nProspective Register for Pheochromocytoma and Paraganglioma: Towards \nImproved Patient Management and Therapeutic Outcomes","eudractNumber":null,"id":9662,"indications":[{"id":"nen","name":"Bösartige Tumoren der Nebenniere"}],"mutations":[],"nctNumber":"NCT03344016 ","phase":null,"recruitmentStart":"2020-05-05T11:51:13+02:00","shortTitle":"Prospheo","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Pylorusresektion versus Pyloruserhalt nach Pancreatoduodenektomie: Eine multizentrische\nrandomisierte aktiv kontrollierte Register-basierte Studie (RRCT) der Chirurgie\nmit dem Deutschen DGAV StuDoQ|Pankreas Register
DRKS00018842

","eudractNumber":null,"id":6237,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2020-12-09T11:36:02+01:00","shortTitle":"PyloResPres","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Qualitätssicherung der Therapie des Ovarialkarzinoms (QS-OVAR) 
DRKS00027253
DRKS00027253DRKS00027253
","eudractNumber":null,"id":8573,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2022-06-03T12:47:13+02:00","shortTitle":"QS - OVAR","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Evaluation of Clinical Management and Outcome in High\nRisk or Recurrent Endometrial Cancer - A Real-World \nObservational Study (QS-Endometrium) ","eudractNumber":null,"id":11933,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn1","name":"Gebärmutterkrebs (Uteruskarzinom)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-01-27T09:48:22+01:00","shortTitle":"QS-Endometrium","therapeutical":false,"therapyLines":[]},{"active":true,"description":"A Randomized Phase II Trial Evaluating Fruquintinib in Combination with Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer without Active Liver Metastases","eudractNumber":"2024-519929-38-00","id":11431,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[],"nctNumber":"NCT06856837","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2025-11-19T12:35:07+01:00","shortTitle":"Quintis","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"}]},{"active":true,"description":"
R-Pola-Glo – A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in previously untreated aggressive B-cell lymphoma patients above 60 years of age ineligible for a fully dosed R-CHOP
","eudractNumber":"2022-003398-51","id":8351,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[{"name":"CD (Cluster of Differentiation)","id":"mt_211"},{"name":"CD20","id":"mt_77"}],"nctNumber":"NCT05798156","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2024-01-02T14:56:14+01:00","shortTitle":"R-Pola-Glo","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTICD20 X ANTI-CD3 BISPECIFIC ANTIBODY, VERSUS INVESTIGATOR’S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1)
","eudractNumber":"2022-502660-20","id":9250,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT06091254","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-12-10T09:10:35+01:00","shortTitle":"R1979-HM-2298 (OLYMPIA-1)","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]}]}